Current Report Filing (8-k)
September 17 2020 - 2:51PM
Edgar (US Regulatory)
0000764195
false
0000764195
2020-09-17
2020-09-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): September 17, 2020
VBI
VACCINES INC. VBI Vaccines Inc/BC
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
|
|
001-37769
|
|
N/A
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
|
|
02142
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
Common
Shares, no par value per share
|
|
VBIV
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On
September 17, 2020, VBI Vaccines Inc. (the “Company”) issued a press release announcing additional biomarker data
from its ongoing Phase 1/2a study evaluating VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate, in recurrent
glioblastoma (GBM) patients presented in an e-poster at The European Society for Medical Oncology (ESMO) Virtual Congress 2020.
A copy of the e-poster being presented and the press release are furnished as Exhibits 99.1 and 99.2 to this Current Report on
Form 8-K and are incorporated by reference herein.
The
Company undertakes no obligation to update, supplement or amend the materials attached hereto.
The
information in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) is being furnished pursuant
to Item 7.01 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date hereof and regardless of any general incorporation language in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI
Vaccines Inc.
|
|
|
|
Date:
September 17, 2020
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff
Baxter
|
|
|
President
and Chief Executive Officer
|
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2023 to Apr 2024